PDF) Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers
Ziv Gan-Or on Twitter: "Despite being completely unclear whether glucosylceramide is relevant is PD, the plans for the trial continued as usual. Now, let's talk about some pre-clinical results, using mouse "PD
venglustat - Drug Hunter
Precision medicine in Parkinson's disease: emerging treatments for genetic Parkinson's disease. - Abstract - Europe PMC
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update - IOS Press
![Top 10 Fabry Disease Clinical Trials [2023 Studies] | Power](https://pwr-og-img.withpower.com/Fabry%20Disease%20research%20studies%20recruiting%20patients%20in%202023%20need%20your%20help.%20Receive%20premium%20care%20&%20cutting%20edge%20treatments%20by%20enrolling%20in%20fabry%20disease%20clinical%20trials%20today..png?md=1 "Top 10 Fabry Disease Clinical Trials [2023 Studies] | Power")
Top 10 Fabry Disease Clinical Trials [2023 Studies] | Power
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020. - Abstract - Europe PMC
Genes | Free Full-Text | The Genetics of Parkinson's Disease and Implications for Clinical Practice
SAT-112 CLINICAL TRIAL OF VENGLUSTAT, A GLUCOSYLCERAMIDE SYNTHASE (GCS) INHIBITOR, IS SUPPORTED BY PRECLINICAL AND PHASE 1 STUDY
Progress towards therapies for disease modification in Parkinson's disease - The Lancet Neurology
Preclinical pharmacology of glucosylceramide synthase inhibitor venglustat in a GBA-related synucleinopathy model | Scientific Reports
Sanofi halts venglustat clinical programme in kidney disease
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020 - IOS Press
PDF) Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Oral Venglustat in Healthy Volunteers
Venglustat | C20H24FN3O2S | CID 60199242 - PubChem
Venglustat, an orally administered glucosylceramide synthase inhibitor: Assessment over 3 years in adult males with classic Fabry disease in an open-label phase 2 study and its extension study - ScienceDirect
Sanofi's venglustat fails another trial, ending pursuit of kidney disease | Fierce Biotech
MOVES-PD Clinical Trial Results - Venglustat - Cure Parkinson's
Ibiglustat (L-Malic acid) (Venglustat (L-Malic acid)) | Glucosylceramide Synthase Inhibitor | MedChemExpress
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update - IOS Press
Pharmacokinetics, Safety, and Tolerability of Single-Dose Orally Administered Venglustat in Healthy Chinese Volunteers | SpringerLink
Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial - ScienceDirect
Gaucher Treatment Report
Cells | Free Full-Text | Recent Advances in the Treatment of Genetic Forms of Parkinson’s Disease: Hype or Hope?
